



## Tricida to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 6, 2021

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 11:50 am PT / 2:50 pm ET. Gerrit Klaerner, Ph.D., Tricida's Founder, President and CEO, will provide a company overview, business update and progress on the company's key initiatives.

A live webcast of the presentation will be accessible on the Tricida website at [IR.Tricida.com](http://IR.Tricida.com). An archive of the webcast will be available for 90 days following the presentation.

### About Tricida

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veveimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. There are no FDA-approved treatments for chronic metabolic acidosis, a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately three million patients with CKD in the United States.

For more information about Tricida, please visit [www.Tricida.com](http://www.Tricida.com).

Contact:

Jackie Cossmon, IRC

Tricida, Inc.

Senior Vice President of Investor Relations and Communications

[IR@Tricida.com](mailto:IR@Tricida.com)



Source: Tricida, Inc.